Homocysteine Test: What a Raised Result Does and Does Not Tell You

What is a homocysteine test?

A homocysteine test is a blood test measuring homocysteine, an amino acid produced during the metabolism of methionine. The body clears it using folate, vitamin B12 and vitamin B6, so a raised level most often signals a shortfall or a processing problem in one of those pathways. MedlinePlus describes its principal use as assessing vitamin B6, B12 and folate status.

What is a normal homocysteine level?

Cleveland Clinic gives a typical range of 5 to 15 micromoles per litre. Reference intervals vary between laboratories and by assay, and homocysteine rises with age and is generally higher in men than in women, so results should be read against the range on your own report.

Many clinicians working in preventive medicine regard results in the upper part of that interval as worth attention rather than as simply normal, particularly when B vitamin status has not been assessed. As with several markers, sitting inside a population reference range and being metabolically optimal are not the same claim.

What causes high homocysteine?

The commonest causes are low folate, low vitamin B12 or low vitamin B6, since all three are required to clear homocysteine. Other contributors include reduced kidney function, hypothyroidism, certain medications, smoking, high alcohol intake, and inherited variation in the enzymes of the methylation pathway. In rare cases, markedly elevated levels indicate homocystinuria, an inherited metabolic disorder usually identified in childhood.

The ordering matters. Renal function should be considered before attributing a raised homocysteine to vitamin status, because the kidney is a major route of homocysteine clearance. Micronutrient shortfalls also rarely occur alone, and vitamin D deficiency symptoms overlap heavily with B vitamin shortfall in presentations of fatigue and low mood.

The methylation pathway, and what it is not

Homocysteine sits at the centre of the methylation pathway, the sequence of enzymatic steps that governs how the body absorbs and activates folate, B12 and B6, clears homocysteine, and regulates neurotransmitters. EVA's DNA analysis examines 23 genes across this pathway. The eight below have the clearest, most clinically actionable evidence, and are the ones we discuss directly with clients.

Common variants in these genes can reduce enzyme efficiency, which is one reason two people with similar diets can carry quite different homocysteine levels. EVA screens more than 200 million genetic variants through OmicsEdge, whose analytical methodology is peer-reviewed and research-backed.

A clarification worth making explicitly, because the terminology causes persistent confusion. The methylation pathway described here concerns nutrient metabolism and cellular function. It is a different subject from epigenetic clocks and DNA methylation age algorithms, which read methylation marks across the genome to estimate biological age. The two share a word and very little else. EVA analyses the methylation pathway. It does not estimate age from methylation patterns, and where EVA does report a biological age it is calculated from blood biomarkers, not from methylation marks.

Does lowering homocysteine reduce heart disease risk?

Raised homocysteine is consistently associated with cardiovascular disease in observational studies. However, large randomised trials of B vitamin supplementation have reliably lowered homocysteine without producing a corresponding reduction in heart attacks or cardiovascular mortality. On current evidence, homocysteine is best treated as a marker of B vitamin and methylation status rather than as a cardiovascular risk factor that treating will, by itself, modify.

This distinction is the reason routine cardiovascular screening with homocysteine has fallen out of general use, a shift reflected in the ordering guidance published by reference laboratories such as ARUP and Mayo Clinic Laboratories. Where cardiovascular risk is the actual question being asked, ApoB is the marker with the stronger evidence base for cardiovascular risk.

Stating this openly is a deliberate choice. A page that implies lowering homocysteine prevents heart attacks would be easier to write and would not survive clinical review.

What about stroke and cognitive decline?

Stroke and cognitive decline tell a different story from heart attack risk. The China Stroke Primary Prevention Trial, a randomised trial of more than 20,000 adults with hypertension, found that adding folic acid to a blood pressure medication reduced first stroke by around a fifth over four and a half years, in a population that was not receiving fortified flour and so started with lower folate status than many Western populations. In cognition, a smaller trial in adults with mild cognitive impairment and homocysteine above 13 micromoles per litre found that high-dose B vitamins slowed the rate of brain shrinkage on MRI over two years, with some evidence of slower cognitive decline as a secondary finding.

Neither result is as clean as the null finding on heart attacks above. Broader reviews of B vitamins in cognitively normal older adults are mixed, and the stroke trial's population had a different starting folate status to the UAE, where flour is voluntarily fortified across much of the market. The fair summary: homocysteine-lowering has shown a measurable stroke benefit in at least one large trial, and a plausible, narrower cognitive benefit concentrated in people who start with both elevated homocysteine and early cognitive change. That is a more encouraging picture than the cardiovascular result, but still not a blanket claim for everyone.

Who should have a homocysteine test?

Homocysteine is most informative in people being assessed for B vitamin deficiency, particularly where B12 deficiency is suspected and a serum B12 result is borderline, since homocysteine and methylmalonic acid both rise in true functional B12 deficiency. It is also used in the investigation of unexplained venous thrombosis, in people with a strong family history of premature cardiovascular disease, and alongside genetic results where variants in the methylation pathway have been identified.

It is not a general population screening test, and it is reasonable to say so.

Reading homocysteine alongside genetic results

A homocysteine measurement and a methylation pathway genotype answer different questions. The genotype indicates capacity: how efficiently the enzymes in the pathway are likely to work. The blood result indicates what is actually happening now, incorporating diet, absorption, kidney function, medication and everything else.

Neither substitutes for the other. A person carrying a reduced-efficiency MTHFR variant may have an entirely normal homocysteine because their folate and B12 intake is sufficient to compensate. A person with no notable variants may have a raised homocysteine because of low B12 absorption. Reading the two together is what makes either one actionable, and it is the reason the Elite DNA and blood package combines them rather than selling them as separate products.

How EVA measures and interprets homocysteine

EVA™ combines DNA analysis through OmicsEdge with blood biomarker testing processed through Unilabs, covering more than 70 blood biomarkers across seven body systems. Results across both are interpreted by the Elite Vita clinical team.

For homocysteine specifically, that means a raised result is read alongside B12, folate, renal function and, for clients on the Elite DNA and Blood package, their methylation pathway genotype. DEVA™, the daily in-app feature, delivers 3 insights, 3 actions and 3 outcomes each day. You can read more about the evidence base and testing standards EVA works to.